Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Brunet Mauri, Maria Salut
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Cordeiro, Anna
  • Gallardo, David|||0000-0003-1615-4592
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Tormo, Mar|||0000-0001-9622-1649
  • Heras, Inmaculada
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Duarte, Rafael|||0000-0002-5240-9815
  • Llano Queipo, María Paz de
  • Bargay, Joan|||0000-0002-6739-3916
  • Sampol, Antonia|||0000-0001-7465-6203
  • Nomdedeu, Meritxell
  • Risueño, Ruth M.|||0000-0003-4048-9536
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Sierra, Jorge|||0000-0002-7966-0356
  • Monzo, Mariano|||0000-0003-2322-4851
  • Navarro, Alfons|||0000-0001-6071-0926
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
Long non-coding RNAs (lncRNAs) are deregulated in several tumors, although their role in acute myeloid leukemia (AML) is mostly unknown.We have examined the expression of the lncRNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) in 241 AML patients. We have correlated HOTAIRM1 expression with a miRNA expression profile. We have also analyzed the prognostic value of HOTAIRM1 expression in 215 intermediate-risk AML (IR-AML) patients.The lowest expression level was observed in acute promyelocytic leukemia (P < 0.001) and the highest in t(6;9) AML (P = 0.005). In 215 IR-AML patients, high HOTAIRM1 expression was independently associated with shorter overall survival (OR:2.04;P = 0.001), shorter leukemia-free survival (OR:2.56; P < 0.001) and a higher cumulative incidence of relapse (OR:1.67; P = 0.046). Moreover, HOTAIRM1 maintained its independent prognostic value within the favorable molecular subgroup (OR: 3.43; P = 0.009). Interestingly, HOTAIRM1 was overexpressed in NPM1-mutated AML (P < 0.001) and within this group retained its prognostic value (OR: 2.21; P = 0.01). Moreover, HOTAIRM1 expression was associated with a specific 33-microRNA signature that included miR-196b (P < 0.001). miR-196b is located in the HOX genomic region and has previously been reported to have an independent prognostic value in AML. miR-196b and HOTAIRM1 in combination as a prognostic factor can classify patients as high-, intermediate-, or low-risk (5-year OS: 24% vs 42% vs 70%; P = 0.004).Determination of HOTAIRM1 level at diagnosis provided relevant prognostic information in IR-AML and allowed refinement of risk stratification based on common molecular markers. The prognostic information provided by HOTAIRM1 was strengthened when combined with miR-196b expression. Furthermore, HOTAIRM1 correlated with a 33-miRNA signature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

  • Robles, Eloy F.
  • Mena-Varas, Maria
  • Barrio, Laura
  • Merino-Cortes, Sara V.
  • Balogh, Péter
  • Du, Ming-Qing
  • Akasaka, Takashi
  • Parker, Anton
  • Roa, Sergio
  • Panizo, Carlos
  • Martin-Guerrero, Idoia
  • Siebert, Reiner
  • Segura, Victor
  • Agirre, Xabier|||0000-0002-6558-9560
  • Macri-Pellizeri, Laura
  • Aldaz, Beatriz
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Zhang, Shaowei
  • Moody, Sarah
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Tousseyn, Thomas
  • Broccardo, Cyril
  • Brousset, Pierre
  • Campos-Sanchez, Elena
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Sánchez García, Isidro
  • Fernandez-Luna, Jose Luis
  • Garcia-Muñoz, Ricardo
  • Pena, Esther
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • González, Marcos
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Climent Bataller, Joan|||0000-0002-8927-6614
  • Ferrandez, Antonio
  • Sagaert, Xavier
  • Melnick, Ari M.
  • Prosper, Felipe|||0000-0001-6115-8790
  • Oscier, David G.
  • Carrasco, Yolanda R.
  • Dyer, Martin J. S.
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2 - 3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3 -deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas. The homeobox NKX2 family of transcriptional factors has been shown to regulate fundamental developmental processes. Here, the authors show that NKX2-3 is a bona fide oncogenic driver in marginal-zone B-cell lymphoma and that it promotes lymphomagenesis by shaping lymphocyte dynamics and promoting BCR signalling.